Fragment-Based Drug Discovery and X-Ray Crystallography

Introduction to Fragment-Based Drug Discovery, by Daniel A. Erlanson

Fragment Screening Using X-Ray Crystallography, by Thomas G. Davies and Ian J. Tickle

Hsp90 Inhibitors and Drugs from Fragment and Virtual Screening, by Stephen Roughley, Lisa Wright, Paul Brough, Andrew Massey and Roderick E. Hubbard

Combining NMR and X-ray Crystallography in Fragment-Based Drug Discovery: Discovery of Highly Potent and Selective BACE-1 Inhibitors, by Daniel F. Wyss, Yu-Sen Wang, Hugh L. Eaton, Corey Strickland, Johannes H. Voigt, Zhaoning Zhu and Andrew W. Stamford

Combining Biophysical Screening and X-Ray Crystallography for Fragment-Based Drug Discovery, by Michael Hennig, Armin Ruf and Walter Huber

Targeting Protein–Protein Interactions and Fragment-Based Drug Discovery, by Eugene Valkov, Tim Sharpe, May Marsh, Sandra Greive and Marko Hyvönen

Fragment Screening and HIV Therapeutics, by Joseph D. Bauman, Disha Patel and Eddy Arnold

Fragment-Based Approaches and Computer-Aided Drug Discovery, by Didier Rognan

• Astex Pharmaceuticals
• Biophysical Screening
• Computer Aided Drug Discovery
• Fragment Screening
• Fragment-Based Drug Discovery
• Hsp90 Inhibitors
• Protein-Protein Interactions
• Review
• Selective BACE-1 Inhibitors
• Virtual Screening

• Astex Pharmaceuticals, Cambridge, United Kingdom

  Thomas G. Davies

• , Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom

  Marko Hyvönen

Policies and ethics